Postoperative nausea and vomiting: low dose versus high dose of remifentanil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000185

Enrollment

126

Registered

2011-09-09

Start date

2011-07-05

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : continuous infusion of propofol and remifentanil using TCI

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients undergoing local excision of benign breast mass with general anesthesia in admission

Exclusion criteria

Exclusion criteria: 1) urgent or emergent case, 2) re-do case, 3) allergy to egg or soybean oil, 4) coronary artery disease, 5) cerebral vascular disease, 6) neurological deficits or psychiatric disorders, 7) history of drug abuse, 8) receiving current medications, 9) concurrent other surgery, 10) renal disease (serum creatinine > 2.0 mg/dL) and 11) severe hepatic disease

Design outcomes

Primary

Measure	Time frame
incidence of postoperative nausea and vomitting	—

Secondary

Measure	Time frame
evaluation of postoperative pain through VAS	—

Countries

Korea, Republic of

Contacts

Public ContactWoon-Seok Kang

Konkuk University

Outcome results